[Tofacitinib].
Tofacitinib is the first Janus kinase inhibitor which was approved for the therapy of rheumatoid arthritis in the USA. Several phase III studies proved the efficacy of Tofacitinib as monotherapy or in combination with established medication. This article discusses the therapeutic potential of this new pharmacological approach and the current data on efficacy and safety of Tofacitinib therapy with special emphasis on a prospective approval in the EU.
Institut für Pharmakologie, Universitätsmedizin Göttingen.
S
S
Döker
Institut für Pharmakologie, Universitätsmedizin Göttingen.
M
M
Dewenter
Institut für Pharmakologie, Universitätsmedizin Göttingen.
A
A
El-Armouche
D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D005060:Europe; D006801:Humans; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib